Docoh
Loading...

SAGE Sage Therapeutics

News

From Benzinga Pro
Needham Maintains Buy on Sage Therapeutics, Raises Price Target to $85
6 Jan 22
News, Price Target, Analyst Ratings
Needham analyst Ami Fadia maintains Sage Therapeutics (NASDAQ:SAGE) with a Buy and raises the price target from $79 to $85.
5 Value Stocks In The Healthcare Sector
27 Dec 21
News
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Where Sage Therapeutics Stands With Analysts
20 Dec 21
Analyst Ratings
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:
SVB Leerink Maintains Market Perform on Sage Therapeutics, Lowers Price Target to $60
20 Dec 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Marc Goodman maintains Sage Therapeutics (NASDAQ:SAGE) with a Market Perform and lowers the price target from $70 to $60.
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
8 Dec 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-Operative Inflammation
Sage Therapeutics and Biogen Announce New Analyses From LANDSCAPE Clinical Development Program Of Zuranolone In MDD Presented At The American College Of Neuropsychopharmacology Congress
8 Dec 21
Biotech, General
Patients receiving zuranolone 50 mg in the WATERFALL Study demonstrated rapid improvements in depressive and anxiety symptoms, as early as the first measured timepoint (Day 3 for HAMD-17 and Day 8 for HAM-A), with
5 Value Stocks To Watch In The Healthcare Sector
6 Dec 21
News
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients
1 Dec 21
Biotech, News, Health Care, Movers, Trading Ideas, General
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
1 Dec 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Sage Therapeutics And Biogen Announce One-Year Zuranolone 50 mg Data In Ongoing Open-Label SHORELINE Study
1 Dec 21
Biotech, General
In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two
12 Health Care Stocks Moving In Friday's After-Market Session
8 Nov 21
Movers
Gainers Kiromic BioPharma (NASDAQ:KRBP) shares increased by 5.26% to $3.0 during Friday's after-market session. The market value of their outstanding shares is at $46.3 million.
What 8 Analyst Ratings Have To Say About Sage Therapeutics
3 Nov 21
Analyst Ratings
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter:
RBC Capital Maintains Sector Perform on Sage Therapeutics, Lowers Price Target to $48
3 Nov 21
News, Price Target, Analyst Ratings
RBC Capital analyst Brian Abrahams maintains Sage Therapeutics (NASDAQ:SAGE) with a Sector Perform and lowers the price target from $52 to $48.
Oppenheimer Maintains Outperform on Sage Therapeutics, Lowers Price Target to $80
3 Nov 21
News, Price Target, Analyst Ratings
Oppenheimer analyst Jay Olson maintains Sage Therapeutics (NASDAQ:SAGE) with a Outperform and lowers the price target from $84 to $80.
10 Biggest Price Target Changes For Wednesday
3 Nov 21
Price Target, Pre-Market Outlook, Analyst Ratings
Needham boosted Paycom Software, Inc. (NYSE: PAYC) price target from $495 to $640. Paycom Software shares fell 0.3% to $551.87 in pre-market trading.
HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $55
3 Nov 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Douglas Tsao maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and lowers the price target from $80 to $55.
How Bad Are Sage Therapeutics's Earnings? | Return On Capital Employed
2 Nov 21
Earnings
Sage Therapeutics (NASDAQ:SAGE) brought in sales totaling $1.44 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 21.17%, resulting in a loss of $130.89 million.
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
2 Nov 21
Biotech, Earnings, News, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Sage Therapeutics Q3 EPS $(2.21) Misses $(1.85) Estimate, Sales $1.44M Miss $1.96M Estimate
2 Nov 21
Earnings, News
Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.85) by 19.46 percent. This is a 8.87 percent decrease over losses of $(2.03) per share
Earnings Scheduled For November 2, 2021
2 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.

Press releases

From Benzinga Pro
Thinking about trading options or stock in Draftkings, Robinhood Markets, ViacomCBS, JinkoSolar, or SAGE Therapeutics?
7 Jan 22
Opinion, Press Releases
NEW YORK, Jan. 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DKNG, HOOD, VIAC, JKS, and SAGE.
Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
4 Jan 22
Press Releases
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today
Sage Therapeutics' Third Annual FutureCast Showcases Data from All Three Brain Health Franchises
14 Dec 21
Press Releases
In the open-label LUMINARY Study, SAGE-718 improved performance from baseline on multiple tests of cognitive function in patients with Alzheimer's disease mild cognitive impairment and mild dementia, consistent with
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
8 Dec 21
Press Releases
Patients receiving zuranolone 50 mg in the WATERFALL Study demonstrated rapid improvements in depressive and anxiety symptoms, as early as the first measured timepoint (Day 3 for HAMD-17 and Day 8 for HAM-A), with
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
1 Dec 21
Press Releases
In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment
Sage Therapeutics to Host Sage FutureCast Webcast
29 Nov 21
Press Releases
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
24 Nov 21
Press Releases
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today
Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
11 Nov 21
Press Releases
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
2 Nov 21
Press Releases
NDA submission for zuranolone for the treatment of MDD expected to be filed in the second half of 2022, with rolling submission planned to begin in early 2022 CORAL Study primary endpoint updated, in line with goal of
Ketamine's Potential As A Treatment For Depression Has Drawn Major Industry Attention
27 Oct 21
Opinion, Press Releases
PALM BEACH, Fla., Oct. 27, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been